OrbitonOpen research workspace →
Novo Nordisk A/S logo

Novo Nordisk A/S

TSX:NOVOLive AI agent

Novo Nordisk is a global healthcare company with over a century of experience in diabetes care and innovation.

Investor website: https://novonordisk.com/

About

Novo Nordisk is a global healthcare company with over a century of experience in diabetes care and innovation. Founded by Marie and August Krogh, the company has a rich history of scientific advancements, particularly in insulin production, which transformed diabetes from a fatal disease into a manageable condition. Novo Nordisk is committed to improving the lives of people with chronic diseases through innovative treatments and a deep understanding of patient needs.

Verified company data

Shares outstanding
4453.9
Fully diluted shares
4463.0
Projects
["Obesity medications\n\n**Saxenda®** \nLiraglutide 3 mg\n\n**Wegovy®** \nSemaglutide\n\n**Wegovy® pill** \nSemaglutide","Diabetes medications\n\nTreatments\n\n**Once-weekly insulin**\n[Awiqli®, insulin icodec](https://www.ema.europa.eu/en/medicines/human/EPAR/awiqli)\n\n**Long-acting insulin**\n[Tresiba®, insulin degludec](https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba) [Xultophy®*, insulin degludec/liraglutide](https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy) [Levemir®, insulin detemir](https://www.ema.europa.eu/en/medicines/human/EPAR/levemir)\n\n**Human insulin**\n[Insulatard®, human insulin](https://www.ema.europa.eu/en/medicines/human/EPAR/insulatard) [Actrapid®, human insulin](https://www.ema.europa.eu/en/medicines/human/EPAR/actrapid) [Mixtard® 30, biphasic human insulin](https://www.ema.europa.eu/en/medicines/human/EPAR/mixtard) [Mixtard® 40, biphasic human insulin](https://www.ema.europa.eu/en/medicines/human/EPAR/mixtard) [Mixtard® 50, biphasic human insulin](https://www.ema.europa.eu/en/medicines/human/EPAR/mixtard)\n\n**Premix insulin**\n[Ryzodeg® 70/30, insulin degludec/insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/ryzodeg) [NovoMix® 30, biphasic insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/novomix) [NovoMix® 50, biphasic insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/novomix) [NovoMix® 70, biphasic insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/novomix)\n\n**Glucagon-like peptide-1 (GLP-1)**\n[Rybelsus®, oral semaglutide](https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus) [Victoza®, liraglutide](https://www.ema.europa.eu/en/medicines/human/EPAR/victoza) [Ozempic®, semaglutide](https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic)\n\n**Fast-acting insulin**\n[Fiasp®, insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp) [NovoRapid® **, insulin aspart](https://www.ema.europa.eu/en/medicines/human/EPAR/novorapid) [NovoRapid® PumpCart®, pre-filled insulin pump cartridge](https://www.ema.europa.eu/en/medicines/human/EPAR/novorapid)\n\n**Oral antidiabetic agents**\n[NovoNorm®, repaglinide](https://www.ema.europa.eu/en/medicines/human/EPAR/novonorm)\n\n**Other drugs**\n[GlucaGen® , Glucagon](https://mri.cts-mrp.eu/portal/fulltext-search?term=Glucagon)","Haemophilia medications\n\n**NovoSeven®** \nRecombinant factor VIIa\n\n**NovoEight®*** \nRecombinant factor VIII\n\n**NovoThirteen®** \nRecombinant factor XIII\n\n**Refixia***** \nNonacog beta pegol; N9/GP\n\n**Esperoct®** \nTuroctocog alfa pegol, N8-GP\n\n**Alhemo®** \nConcizumab-mtci","Growth disorder medications\n\n**Norditropin®** \nSomatropin (rDNA origin)\n\n**Sogroya™** \nSomapacitan","Hormone replacement therapy\n\nVagifem®\nEstradiol hemihydrate\n\n**Activelle®** \nEstradiol/norethisterone acetate\n\n**Kliogest®** \nEstradiol/norethisterone acetate\n\n**Novofem®** \nEstradiol/norethisterone acetate\n\n**Trisequens®** \nEstradiol/norethisterone acetate\n\nEstrofem®\nEstradiol"]
Leadership
Maziar Mike Doustdar (President and Chief Executive Officer (CEO), Joined Novo Nordisk in 1992, held various positions in finance, IT, logistics, operations, and marketing, promoted to CEO in August 2025.), Jamey Millar (Executive Vice President, US Operations, Joined Novo Nordisk in February 2026, brings over 30 years of leadership and industry experience, previously worked for UnitedHealth Group and GlaxoSmithKline.)

Verified data last updated:

Recent filings